Nanobiotix Nanoparticle Targets Radiotherapy Effects on Tumors

LONDON – Nanobiotix SA presented positive safety data from the first clinical study of NBTXR3, a nanoparticle drug that enhances the effects of radiotherapy on tumor cells without damaging healthy tissue, at the American Society of Clinical Oncology (ASCO) meeting in Chicago on Saturday.